Pfizer Discontinues Global Development of Bococizumab
Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor Pfizer Inc. announced the discontinuation of the global clinical development program for bococizumab, its investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor (PCSK9i). The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for lipid-lowering agents, indicates…